RxDoctor Payments Data

Kristen Rice, MD

Dermatology · Tulsa, OKNPI 1871826115

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.4% of the total across 444 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations.

$9,076in general payments, 2019–2025

Across 444 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • E.r. Squibb & Sons, L.L.C.$765
  • Novartis$719
  • Johnson & Johnson$694
  • Amgen$651
  • Lilly USA, LLC$531
  • plus $4K from 25 others
$47,600in research payments, 2019–2025

Across 35 payments — averaging $1360.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Galderma Research & Development, LLC$45K
  • Dermavant Sciences, Inc.$3K

What the payments were for

  • Speaking & faculty fees$5006%
  • Food & beverage$8,48193%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,076 in reported general payments places this provider in the 75th percentile of 114 dermatology providers in Oklahoma.

See all dermatology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$411,650
Medicare patients
883
Services billed
8,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol Propionate112$4,569
Ketoconazole268$4,100
Doxycycline Hyclate108$3,349
Fluocinonide76$2,291
Triamcinolone Acetonide95$1,232
Metronidazole25$1,052
Mycophenolate Mofetil21$958
Hydrocortisone116$950
ValacyclovirValacyclovir Hcl41$925
Minoxidil124$925
Fluconazole55$659
Clindamycin Phosphate16$607
Finasteride38$446
Mupirocin55$346
Terbinafine Hcl12$235

Paid to pharmacies, not to this prescriber.

Other dermatology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →